These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1211 related articles for article (PubMed ID: 27190362)

  • 1. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
    Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
    Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
    Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
    Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-transplant crossmatch-negative donor-specific anti-HLA antibody predicts acute antibody-mediated rejection but not long-term outcomes in kidney transplantation: an analysis of the Korean Organ Transplantation Registry.
    Lee H; Lee H; Sun IO; Park JH; Park JW; Ban TH; Yang J; Kim MS; Yang CW; Chung BH;
    Front Immunol; 2024; 15():1420351. PubMed ID: 39055708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-MFI (median fluorescence intensity) pre-transplant DSA (donor specific antibodies) leading to anamnestic antibody mediated rejection in live-related donor kidney transplantation.
    Chauhan R; Tiwari AK; Aggarwal G; Gowri Suresh L; Kumar M; Bansal SB
    Transpl Immunol; 2023 Dec; 81():101931. PubMed ID: 37730185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
    Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
    Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients.
    Lorenz M; Regele H; Schillinger M; Kletzmayr J; Haidbauer B; Derfler K; Druml W; Böhmig GA
    Transplantation; 2005 Mar; 79(6):696-701. PubMed ID: 15785376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients.
    Lee KW; Park JB; Cho CW; Lee N; Yoo H; Kim K; Park H; Kang ES; Huh W; Kim S
    Ann Transplant; 2017 Mar; 22():166-176. PubMed ID: 28348361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
    Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
    Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients.
    Adebiyi OO; Gralla J; Klem P; Freed B; Davis S; Wiseman AC; Cooper JE
    Am J Transplant; 2016 Dec; 16(12):3458-3467. PubMed ID: 27140940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplant low level HLA antibody shows a composite poor outcome in long-term outcome of renal transplant recipients.
    Tian J; Li D; Alberghini TV; Rewinski M; Guo N; Bow LM
    Ren Fail; 2015 Mar; 37(2):198-202. PubMed ID: 25565259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
    Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
    Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-transplant donor specific antibody and its clinical significance in kidney transplantation.
    Thammanichanond D; Ingsathit A; Mongkolsuk T; Rattanasiri S; Kantachuvesiri S; Sakhonrat C; Leenanupan C; Worawichawongs S; Kitpoka P
    Asian Pac J Allergy Immunol; 2012 Mar; 30(1):48-54. PubMed ID: 22523907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy.
    Morath C; Beimler J; Opelz G; Scherer S; Schmidt J; Macher-Goeppinger S; Klein K; Sommerer C; Schwenger V; Zeier M; Süsal C
    Transpl Int; 2012 May; 25(5):506-17. PubMed ID: 22372718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.